西罗莫司适用于什么病症？

Recommended for use in combination with cyclosporine and corticosteroids, taken orally once daily. To reduce differences in the absorption of sirolimus, patients should choose to take it regularly with or without food. Tablets should not be broken or chewed. So, what diseases is Biocon India’s sirolimus suitable for?

Sirolimus is indicated for the prevention of organ rejection in patients 13 years of age or older who have received kidney transplants. Recommended for use in combination with cyclosporine and corticosteroids.

Sirolimus tablets were approved in 2002 and officially launched in China, bringing new treatment opportunities and options to many domestic kidney transplant patients. Previously, the drug had been approved by the FDA in 1999 and was officially launched in the United States.

Biocon is one of India's three largest biotech companies and an emerging global biopharmaceutical company that is committed to reducing the cost of treatment for chronic diseases such as diabetes, cancer and autoimmune disease patients by leveraging India's cost advantages and partners to provide affordable healthcare solutions to healthcare systems around the world.

As a mammalian target of rapamycin inhibitor, sirolimus tablets are a macrolide antibiotic isolated from actinomycete cultures. It was originally developed as an antifungal drug, but it showed immunosuppressive effects in animal models and was later approved as a maintenance immunosuppressant.

Sirolimus has attracted clinical attention and is widely used because of its advantages such as non-nephrotoxicity, anti-tumor, and ability to reduce the incidence of cytomegalovirus infection.

Can be used to improve the condition of lymphoma. Sirolimus blocks signal transduction through different cytokine receptors and blocks the process of T lymphocytes and other cells from the G1 phase to the S phase, thereby exerting an immunosuppressive effect. Sirolimus is a macrolide antibiotic that is used long-term to help improve disease.